Table 1 Demographic Table: This will include all the following information in both Enoxaparin and Rivaroxaban Arm
Variables | Enoxaparin 80 (53.3%) | Rivaroxaban 70 (46.7%) | p-value |
|---|---|---|---|
Baseline Demographics | |||
Age in years | 48.67 ± 14.45 | 51.84 ± 13.49 | 0.17 |
Gender | 0.25 | ||
Male | 37 (46.2%) | 39 (55.7%) | |
Female | 43 (53.8%) | 31 (44.3%) | |
BMI | 23.63 ± 4.64 | 25.20 ± 5.43 | 0.05 |
Baseline Co-Morbids | |||
Coronary Artery Disease | 1.00 | ||
No | 79 (98.8%) | 69 (98.6%) | |
Yes | 1 (1.2%) | 1 (1.4%) | |
Hypertension | 0.30 | ||
No | 70 (87.5%) | 57 (81.4%) | |
Yes | 10 (12.5%) | 13 (18.6%) | |
Diabetes Mellitus | 0.49 | ||
No | 64 (80.0%) | 59 (84.3%) | |
Yes | 16 (20.0%) | 11 (15.7%) | |
Creatinine Clearance | 0.78 | ||
Less than 60 | 8 (10.0%) | 8 (11.4%) | |
Equal or above 60 | 72 (90.0%) | 62 (88.6%) | |
Baseline Malignancy History | |||
Active Cancer | 0.58 | ||
No | 9 (11.2%) | 6 (8.6%) | |
Yes | 71 (88.8%) | 64 (91.4%) | |
Cancer Type | 0.07 | ||
GI | 23 (28.8%) | 18 (26.1%) | |
Breast | 9 (11.2%) | 17 (24.6%) | |
GU | 21 (26.2%) | 22 (31.9%) | |
Lungs | 4 (5.0%) | 3 (4.3%) | |
Misc. | 23 (28.8%) | 9 (13.0%) | |
Disease status | 0.89 | ||
Non-metastatic | 42 (52.5%) | 36 (51.4%) | |
Metastatic | 38 (47.5%) | 34 (48.6%) | |
Chemotherapy | 0.82 | ||
No | 30 (37.5%) | 25 (35.7%) | |
Yes | 50 (62.5%) | 45 (64.3%) | |
Baseline Laboratory Findings | |||
Hemoglobin Level | 10.65 ± 2.19 | 13.12 ± 14.21 | 0.13 |
Platelet Level | 274.93 ± 140.70 | 302.60 ± 153.84 | 0.25 |
Leukocyte Count | 9.67 ± 4.96 | 8.16 ± 3.79 | 0.04 |
Albumin | 3.46 ± 0.78 | 3.75 ± 0.56 | 0.01 |
Creatinine | 0.81 ± 0.64 | 0.73 ± 0.27 | 0.34 |
Creatinine clearance | 128.02 ± 82.76 | 114.30 ± 45.65 | 0.22 |